Sales of the key ... The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below. From a valuation standpoint, J&J is reasonably valued. Going by the price ...

Sales in J&J’s Innovative Medicines segment are expected to have been driven by higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains.